The cancer therapeutics developer has filed to float on the Nasdaq Global Market, with Taiho Ventures set to achieve an exit.

Werewolf Therapeutics, a US-based oncology therapy developer backed by pharmaceutical firm Taiho, filed for a $100m initial public offering (IPO) on the Nasdaq Global Market yesterday. Founded by life sciences investment firm MPM Capital with an undisclosed amount of seed funding in 2017, Werewolf is developing cancer-focused biotherapeutics which involve using its protein engineering platform…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.